Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and Clinical Trial Agreements (Tables)

Sponsored Research and Clinical Trial Agreements (Tables)

9 Months Ended

Sep. 30, 2019

Schedule of research and development for sponsored research and clinical trial agreements

For the three and nine months ended September 30, 2019 and 2018, Aevitas recorded the following expense in research and development for sponsored research and clinical trial agreements:


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
($ in thousands)	2019		2018		2019		2018
UMass – AAV	$	—	$	188	$	—	$	564
UPenn – AAV		255		250		755		250
Duke – AAV		17		—		17		—
Total	$	272	$	438	$	772	$	814

Mustang [Member]

Schedule of research and development for sponsored research and clinical trial agreements

For the three and nine months ended September 30, 2019 and 2018, Mustang recorded the following expense in research and development for sponsored research and clinical trial agreements:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in thousands)	2019		2018		2019		2018
City of Hope	$	500	$	500	$	1,500	$	1,500
City of Hope - CD123		269		123		1,028		387
City of Hope - IL13Ra2		244		346		811		849
City of Hope - Manufacturing		114		114		343		344
Fred Hutch - CD20		49		255		690		938
BIDMC - CRISPR		—		69		69		69
Total	$	1,176	$	1,407	$	4,441	$	4,087